A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

Melanoma Research

Volumn 11, Issue 3, 2001, Pages 309-313

  Mc Clay, E F ^a   Mc Clay, M E T ^a   Monroe, L ^a   Jones, J A ^a   Winski, P J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cisplatin; Melanoma; Metastatic; Tamoxifen

Indexed keywords

CISPLATIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; TAMOXIFEN; TIME FACTORS;

EID: 0034959709     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200106000-00014     Document Type: Article

References (20)

1. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma
2. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: A biologically important observation
3. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma
4. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells
5. Combination chemo/hormonal therapy in the treatment of malignant melanoma
6. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
7. The importance of tamoxifen to a cisplatin containing regimen in the treatment of metastatic melanoma
8. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-Year follow-up
9. Effective chemotherapy for melanoma after treatment with interleukin-2
10. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: A University of South Florida and H. Lee Moffitt Melanoma Center study
11. Modulation of cisplatin resistance in human malignant melanoma cells
12. Tamoxifen delays the in vitro development of resistance to cisplatin in human malignancies
13. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies
14. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin
15. BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): Results of a randomized phase II study
16. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma
17. A phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
18. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high-risk melanoma
19. Interferon alfa-2a adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
20. Adjuvant systemic therapy